Scorpion’s CEO Axel Hoos, CMO bite the dust as oncology biotech brings in new leadership
Executive ChangePhase 1PROTACs
Preview
Source: FierceBiotech
Industry veteran Axel Hoos has led Scorpion Therapeutics for the past two and a half years.
Scorpion Therapeutics is entering its “next phase of growth” in 2024, leaving former CEO Axel Hoos, M.D., Ph.D., and ex-Chief Medical Officer Michael Streit, M.D., behind.
Industry veteran Hoos has led the Boston-based company since July 2021, when he joined from GSK. At the time, Hoos had taken the reins from interim CEO Adam Friedman, M.D., Ph.D. Now, Friedman is taking back the top title, this time sans the temporary designation, according to a Thursday press release that mentioned Hoos just twice.
Friedman is part of Scorpion’s founding team and most recently served as the biotech’s president of corporate strategy and business development, a role in which he helped secure partnerships with AstraZeneca and Pierre Fabre. Before Scorpion, Friedman clocked in time at Raze Therapeutics and Vivid Biosciences, the latter of which he co-founded.
Scorpion is also replacing Streit, who was the first to fill the company’s chief medical officer position. Streit joined Scorpion in 2022 from Sanofi, where he had most recently served as vice president and senior project head. Upon joining Scorpion, Streit was tasked with guiding the biotech as it advanced two oncology candidates toward the clinic in 2023.
Now, with the two candidates in phase 1 development, Mark Chao, M.D., Ph.D., will take over as CMO. He joins from TenSixteen Bio, a precision therapeutics company where he served as co-founder and CEO.
But that’s not all. Scorpion has also promoted Erica Jackson, Ph.D., to chief discovery officer. Previously serving as the company’s executive vice president of biology, Jackson will now be responsible for discovery strategy and the biotech’s preclinical portfolio. Before Scorpion, she served as senior director of tumor dependencies and oncology discovery at AbbVie.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.